LVTX LAVA Therapeutics | $1.03
+4.2% | 12/12/2024 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of LAVA Therapeutics (NASDAQ:LVTX) on 12/12/2024 |
QTTB Q32 Bio | $3.59
+7.5% | 12/11/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Q32 Bio (NASDAQ:QTTB) on 12/11/2024 |
PDCO Patterson Companies | $30.86
-0.2% | 12/11/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Patterson Companies (NASDAQ:PDCO) on 12/11/2024 |
ANIP ANI Pharmaceuticals | $53.35
-1.7% | 12/11/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | N/A | View details for Leerink Partnrs rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/11/2024 |
MYGN Myriad Genetics | $13.36
+1.4% | 12/9/2024 | Downgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Myriad Genetics (NASDAQ:MYGN) on 12/9/2024 |
RLMD Relmada Therapeutics | $0.36
+2.9% | 12/4/2024 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Relmada Therapeutics (NASDAQ:RLMD) on 12/4/2024 |
|
OKUR OnKure Therapeutics | $8.38
+4.1% | 12/5/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy | | N/A | View details for Leerink Partnrs rating of OnKure Therapeutics (NASDAQ:OKUR) on 12/5/2024 |
ZTS Zoetis | $164.84
+0.8% | 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst D. Clark | Strong-Buy | | N/A | View details for Leerink Partnrs rating of Zoetis (NYSE:ZTS) on 12/2/2024 |
IDXX IDEXX Laboratories | $412.26
+0.8% | 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst D. Clark | Strong-Buy | | N/A | View details for Leerink Partnrs rating of IDEXX Laboratories (NASDAQ:IDXX) on 12/2/2024 |
ELAN Elanco Animal Health | $11.63
-1.6% | 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst D. Clark | Hold | | N/A | View details for Leerink Partnrs rating of Elanco Animal Health (NYSE:ELAN) on 12/2/2024 |
CLYM Climb Bio | $1.95
| 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy | | N/A | View details for Leerink Partnrs rating of Climb Bio (NASDAQ:CLYM) on 12/2/2024 |
JANX Janux Therapeutics | $56.83
+0.1% | 11/22/2024 | Upgraded by | Leerink Partnrs | Analyst J. La. Rosa | Strong-Buy | | N/A | View details for Leerink Partnrs rating of Janux Therapeutics (NASDAQ:JANX) on 11/22/2024 |
ABBV AbbVie | $175.58
+2.4% | 11/22/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of AbbVie (NYSE:ABBV) on 11/22/2024 |
ACRS Aclaris Therapeutics | $2.72
-1.8% | 11/19/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/19/2024 |
CMPX Compass Therapeutics | $1.38
+0.7% | 11/15/2024 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Compass Therapeutics (NASDAQ:CMPX) on 11/15/2024 |
MASS 908 Devices | $2.06
+6.2% | 11/13/2024 | Downgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of 908 Devices (NASDAQ:MASS) on 11/13/2024 |
BMY Bristol-Myers Squibb | $57.33
+1.8% | 11/12/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Bristol-Myers Squibb (NYSE:BMY) on 11/12/2024 |
XRAY DENTSPLY SIRONA | $18.70
+1.2% | 11/7/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 11/7/2024 |
ZYME Zymeworks | $14.14
+4.1% | 11/7/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Zymeworks (NYSE:ZYME) on 11/7/2024 |
BEAM Beam Therapeutics | $29.01
+8.0% | 11/6/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 11/6/2024 |
IDYA IDEAYA Biosciences | $25.61
+3.3% | 11/5/2024 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 11/5/2024 |
ZURA Zura Bio | $2.28
-2.6% | 11/4/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | High | View details for Leerink Partnrs rating of Zura Bio (NASDAQ:ZURA) on 11/4/2024 |
NVST Envista | $18.70
+3.7% | 10/31/2024 | Upgraded by | Leerink Partnrs | Analyst M. Cherny | Strong Sell -> Hold | | Medium | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 10/31/2024 |
TENX Tenax Therapeutics | $5.61
+0.9% | 10/24/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy | | High | View details for Leerink Partnrs rating of Tenax Therapeutics (NASDAQ:TENX) on 10/24/2024 |
GILD Gilead Sciences | $92.57
+1.6% | 10/21/2024 | Upgraded by | Leerink Partnrs | Analyst D. Graybosch | Hold -> Strong-Buy | | High | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/21/2024 |
VYGR Voyager Therapeutics | $5.75
+1.1% | 10/16/2024 | Upgraded by | Leerink Partnrs | Analyst L. Nsongo | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Voyager Therapeutics (NASDAQ:VYGR) on 10/16/2024 |
STOK Stoke Therapeutics | $11.68
+3.4% | 10/11/2024 | Upgraded by | Leerink Partnrs | Analyst M. Goodman | Strong-Buy | | Low | View details for Leerink Partnrs rating of Stoke Therapeutics (NASDAQ:STOK) on 10/11/2024 |
MNMD Mind Medicine (MindMed) | $7.16
+2.1% | 10/11/2024 | Upgraded by | Leerink Partnrs | Analyst M. Goodman | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 10/11/2024 |
MOLN Molecular Partners | $5.08
-2.7% | 10/7/2024 | Upgraded by | Leerink Partnrs | Analyst J. Chang | Strong-Buy | | Low | View details for Leerink Partnrs rating of Molecular Partners (NASDAQ:MOLN) on 10/7/2024 |
HUM Humana | $247.10
+4.8% | 10/2/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy -> Hold | | Medium | View details for Leerink Partnrs rating of Humana (NYSE:HUM) on 10/2/2024 |
AGIO Agios Pharmaceuticals | $35.42
-1.1% | 9/27/2024 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy -> Hold | | Medium | View details for Leerink Partnrs rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 9/27/2024 |
REGN Regeneron Pharmaceuticals | $701.85
-0.9% | 9/24/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy -> Hold | | Medium | View details for Leerink Partnrs rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 9/24/2024 |
ICLR ICON Public | $207.51
+1.4% | 9/18/2024 | Upgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy | | Low | View details for Leerink Partnrs rating of ICON Public (NASDAQ:ICLR) on 9/18/2024 |
ORKA Oruka Therapeutics | $20.31
-2.2% | 9/17/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy | | Low | View details for Leerink Partnrs rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/17/2024 |
FULC Fulcrum Therapeutics | $4.35
+7.9% | 9/12/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Strong-Buy -> Hold | | High | View details for Leerink Partnrs rating of Fulcrum Therapeutics (NASDAQ:FULC) on 9/12/2024 |
TRVI Trevi Therapeutics | $4.05
-2.4% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Trevi Therapeutics (NASDAQ:TRVI) on 9/9/2024 |
PRTC PureTech Health | $20.28
-3.8% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | High | View details for Leerink Partnrs rating of PureTech Health (NASDAQ:PRTC) on 9/9/2024 |
PLRX Pliant Therapeutics | $13.21
-0.7% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Low | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 9/9/2024 |
MNKD MannKind | $6.85
+8.7% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Medium | View details for Leerink Partnrs rating of MannKind (NASDAQ:MNKD) on 9/9/2024 |
KYMR Kymera Therapeutics | $40.66
+3.9% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 9/9/2024 |
Has Trump Finally Gone Too Far? (Ad) Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks.
It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives.
But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars.
And here's the good news. Register For The Webinar To Discover |
IRWD Ironwood Pharmaceuticals | $4.45
+14.7% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Hold | | Medium | View details for Leerink Partnrs rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 9/9/2024 |
IMUX Immunic | $1.00
-3.8% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | High | View details for Leerink Partnrs rating of Immunic (NASDAQ:IMUX) on 9/9/2024 |
GLPG Galapagos | $26.76
+1.5% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Hold | | Medium | View details for Leerink Partnrs rating of Galapagos (NASDAQ:GLPG) on 9/9/2024 |
GERN Geron | $3.49
-4.6% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Low | View details for Leerink Partnrs rating of Geron (NASDAQ:GERN) on 9/9/2024 |
TXG 10x Genomics | $14.04
+3.2% | 9/3/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy | | Low | View details for Leerink Partnrs rating of 10x Genomics (NASDAQ:TXG) on 9/3/2024 |
PEN Penumbra | $242.54
-0.4% | 9/3/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Strong-Buy | | Low | View details for Leerink Partnrs rating of Penumbra (NYSE:PEN) on 9/3/2024 |
NARI Inari Medical | $55.45
+1.9% | 9/3/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Hold | | Low | View details for Leerink Partnrs rating of Inari Medical (NASDAQ:NARI) on 9/3/2024 |
ARDT Ardent Health Partners | $16.01
-0.2% | 8/12/2024 | Upgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy | | Low | View details for Leerink Partnrs rating of Ardent Health Partners (NYSE:ARDT) on 8/12/2024 |
ARCT Arcturus Therapeutics | $15.48
+4.3% | 8/12/2024 | Upgraded by | Leerink Partnrs | Analyst L. Nsongo | Strong-Buy | | Low | View details for Leerink Partnrs rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/12/2024 |
PGNY Progyny | $14.34
+1.1% | 8/7/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 8/7/2024 |
TBPH Theravance Biopharma | $9.59
-1.4% | 8/6/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Theravance Biopharma (NASDAQ:TBPH) on 8/6/2024 |
WAT Waters | $368.16
+2.1% | 8/1/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Hold -> Strong-Buy | | Low | View details for Leerink Partnrs rating of Waters (NYSE:WAT) on 8/1/2024 |
TECX Tectonic Therapeutic | $47.44
+7.7% | 7/24/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy | | Low | View details for Leerink Partnrs rating of Tectonic Therapeutic (NASDAQ:TECX) on 7/24/2024 |
IONS Ionis Pharmaceuticals | $35.63
+0.1% | 7/24/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Hold -> Strong-Buy | | Low | View details for Leerink Partnrs rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 7/24/2024 |
ALMS Alumis | $8.82
+2.2% | 7/23/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy | | Low | View details for Leerink Partnrs rating of Alumis (NASDAQ:ALMS) on 7/23/2024 |
CELC Celcuity | $12.46
+3.8% | 7/22/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy | | Low | View details for Leerink Partnrs rating of Celcuity (NASDAQ:CELC) on 7/22/2024 |
BNTC Benitec Biopharma | $11.41
-6.2% | 7/22/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Strong-Buy | | Low | View details for Leerink Partnrs rating of Benitec Biopharma (NASDAQ:BNTC) on 7/22/2024 |
EHC Encompass Health | $94.45
+0.7% | 7/10/2024 | Upgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy | | Low | View details for Leerink Partnrs rating of Encompass Health (NYSE:EHC) on 7/10/2024 |
HLVX HilleVax | $1.86
+1.6% | 7/9/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of HilleVax (NASDAQ:HLVX) on 7/9/2024 |
RVTY Revvity | $112.56
+1.8% | 7/8/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy | | Low | View details for Leerink Partnrs rating of Revvity (NYSE:RVTY) on 7/8/2024 |
SDGR Schrödinger | $19.44
+0.7% | 7/2/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Strong-Buy | | Low | View details for Leerink Partnrs rating of Schrödinger (NASDAQ:SDGR) on 7/2/2024 |
SLDB Solid Biosciences | $4.16
+3.7% | 6/24/2024 | Upgraded by | Leerink Partnrs | Analyst J. Schwartz | Hold -> Strong-Buy | | Low | View details for Leerink Partnrs rating of Solid Biosciences (NASDAQ:SLDB) on 6/24/2024 |
QTTB Q32 Bio | $3.59
+7.5% | 5/21/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy | | Low | View details for Leerink Partnrs rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $0.50
-0.7% | 5/14/2024 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/14/2024 |
EHAB Enhabit | $7.65
-0.6% | 5/14/2024 | Upgraded by | Leerink Partnrs | Analyst W. Mayo | Strong Sell -> Hold | | Low | View details for Leerink Partnrs rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AIRS AirSculpt Technologies | $5.35
-2.6% | 5/14/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
AQST Aquestive Therapeutics | $3.65
+0.3% | 5/10/2024 | Upgraded by | Leerink Partnrs | Analyst R. Ruiz | Strong-Buy | | Low | View details for Leerink Partnrs rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $13.36
+1.4% | 5/8/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
BPMC Blueprint Medicines | $90.14
+1.4% | 5/6/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Underperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $44.36
+1.3% | 5/1/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 5/1/2024 |
XOMA XOMA | $27.13
+8.0% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partnrs rating of XOMA (NASDAQ:XOMA) on 4/29/2024 |
LXRX Lexicon Pharmaceuticals | $0.71
-1.2% | 4/30/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
IMCR Immunocore | $28.33
-0.3% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
NGNE Neurogene | $22.64
+2.5% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
TNDM Tandem Diabetes Care | $35.91
+7.9% | 4/25/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
CVAC CureVac | $2.87
-4.0% | 4/25/2024 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
RNAC Cartesian Therapeutics | $19.02
-1.3% | 4/23/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $14.55
-3.0% | 4/16/2024 | Reiterated by | Leerink Partnrs | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partnrs rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $7.16
+2.1% | 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst R. Li | Outperform | | Low | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $32.63
+7.8% | 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ARDX Ardelyx | $4.82
+2.8% | 4/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $4.01
+0.8% | 4/3/2024 | Reiterated by | Leerink Partnrs | Analyst J. Park | Outperform | | Low | View details for Leerink Partnrs rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $84.22
-0.5% | 4/1/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $4.95
-2.4% | 3/25/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
RGLS Regulus Therapeutics | $1.59
+2.6% | 3/18/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.40
+4.7% | 3/14/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $4.05
+2.3% | 3/11/2024 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $7.62
+2.8% | 3/6/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $11.18
-1.2% | 3/5/2024 | Upgraded by | Leerink Partnrs | Analyst R. Ruiz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $4.00
+3.4% | 3/4/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad) Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. |
IDYA IDEAYA Biosciences | $25.61
+3.3% | 2/23/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 2/23/2024 |
DOCS Doximity | $57.83
+4.8% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $10.71
+1.5% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Certara (NASDAQ:CERT) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $18.70
+1.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RLAY Relay Therapeutics | $4.16
-2.3% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 2/22/2024 |
PGNY Progyny | $14.34
+1.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
NVST Envista | $18.70
+3.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Underperform | | Low | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 2/26/2024 |
NUVL Nuvalent | $84.22
-0.5% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 2/22/2024 |
LH Laboratory Co. of America | $228.61
+0.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
DGX Quest Diagnostics | $153.10
+1.0% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
COGT Cogent Biosciences | $7.84
+0.5% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Cogent Biosciences (NASDAQ:COGT) on 2/22/2024 |
ARVN Arvinas | $18.48
+3.6% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Arvinas (NASDAQ:ARVN) on 2/22/2024 |
ALGN Align Technology | $211.06
-1.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $3.48
+4.8% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
WBA Walgreens Boots Alliance | $9.55
+2.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
TDOC Teladoc Health | $9.44
+5.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
PINC Premier | $21.76
+1.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Market Perform | | Low | View details for Leerink Partnrs rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $30.86
-0.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $12.52
-0.8% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $579.74
+0.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of McKesson (NYSE:MCK) on 2/26/2024 |
IQV IQVIA | $197.27
+3.0% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HSIC Henry Schein | $69.82
+1.3% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
HIMS Hims & Hers Health | $26.20
-0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $4.44
-1.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
CVS CVS Health | $44.36
+1.3% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 2/26/2024 |
COR Cencora | $227.69
+0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $118.28
+1.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
APLT Applied Therapeutics | $0.88
-13.7% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $0.83
+2.2% | 2/21/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
ENGN enGene | $5.83
-2.2% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
BTSG BrightSpring Health Services | $17.27
+1.3% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst W. Mayo | Outperform | | Low | View details for Leerink Partnrs rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
SYBX Synlogic | $1.42
+3.5% | 2/9/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $263.38
+0.8% | 2/7/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $359.58
-0.2% | 2/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $3.14
+7.5% | 1/31/2024 | Upgraded by | Leerink Partnrs | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $11.53
+3.5% | 1/30/2024 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $10.97
-1.0% | 1/29/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $1.69
+9.7% | 1/23/2024 | Reiterated by | Leerink Partnrs | Analyst J. La. Rosa | Outperform | | Low | View details for Leerink Partnrs rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AGL agilon health | $1.97
+4.8% | 1/8/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of agilon health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $0.40
-10.2% | 12/22/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $13.51
+2.4% | 12/19/2023 | Upgraded by | Leerink Partnrs | Analyst J. Schwartz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
NBTX Nanobiotix | $3.10
-5.5% | 12/8/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TRML Tourmaline Bio | $20.65
+1.5% | 12/7/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Tourmaline Bio (NASDAQ:TRML) on 12/7/2023 |
MOR MorphoSys | $18.96
| 12/6/2023 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of MorphoSys (NASDAQ:MOR) on 12/6/2023 |
TNYA Tenaya Therapeutics | $1.67
+18.4% | 11/30/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $6.28
+4.0% | 11/28/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $7.65
-1.4% | 11/14/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
ACRS Aclaris Therapeutics | $2.72
-1.8% | 11/13/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/13/2023 |
ZNTL Zentalis Pharmaceuticals | $3.00
+2.4% | 11/7/2023 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $3.14
+7.5% | 10/30/2023 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad) Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. |
BEAM Beam Therapeutics | $29.01
+8.0% | 10/20/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $6.31
+9.2% | 10/18/2023 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
PLRX Pliant Therapeutics | $13.21
-0.7% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 10/16/2023 |
KYMR Kymera Therapeutics | $40.66
+3.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Market Perform | | Low | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/16/2023 |
VCEL Vericel | $56.50
+2.8% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
TNDM Tandem Diabetes Care | $35.91
+7.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $81.17
+0.5% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
PODD Insulet | $266.57
+3.9% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
INSP Inspire Medical Systems | $187.77
+1.3% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
EW Edwards Lifesciences | $74.81
+1.2% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
DXCM DexCom | $80.04
+5.6% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
GILD Gilead Sciences | $92.57
+1.6% | 10/11/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/11/2023 |
AMGN Amgen | $263.38
+0.8% | 10/11/2023 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
ACLX Arcellx | $75.54
+0.4% | 10/12/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Outperform | | Low | View details for Leerink Partnrs rating of Arcellx (NASDAQ:ACLX) on 10/12/2023 |
SPRY ARS Pharmaceuticals | $11.18
-1.2% | 9/21/2023 | Downgraded by | Leerink Partnrs | Analyst R. Ruiz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
TSBX Turnstone Biologics | $0.49
+6.4% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Turnstone Biologics (NASDAQ:TSBX) on 8/15/2023 |
DSGN Design Therapeutics | $6.25
+4.3% | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $48.87
+4.6% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
RLAY Relay Therapeutics | $4.16
-2.3% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NUVL Nuvalent | $84.22
-0.5% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $25.61
+3.3% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
EXEL Exelixis | $33.29
-1.2% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
QTRX Quanterix | $10.50
+5.1% | 8/8/2023 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
NVCR NovoCure | $30.80
+1.3% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
WVE Wave Life Sciences | $13.51
+2.4% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Market Perform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 8/4/2023 |
BLTE Belite Bio | $64.12
+1.1% | 7/26/2023 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
